Platelet production from induced pluripotent stem cells

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 9, 2017, Pages 1717-1727

  Sugimoto, N ^a   Eto, K ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

bioreactors; blood platelets; induced pluripotent stem cells; megakaryocytes; transfusion reaction

Indexed keywords

ADAM10 ENDOPEPTIDASE; ARF PROTEIN; BONE MORPHOGENETIC PROTEIN 4; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIBROBLAST GROWTH FACTOR 2; GLYCOPROTEIN IB ALPHA; HLA ANTIGEN CLASS 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MYC PROTEIN; PROTEIN BCL XL; RANTES; SPHINGOSINE 1 PHOSPHATE; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TAL1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BCL XL GENE; BM11 GENE; CELL AGING; CELL DIFFERENTIATION; CELL EXPANSION; CELL INVASION; CELL MATURATION; CELL PROLIFERATION; DNA CONTENT; EMBRYONIC STEM CELL; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; INDUCED PLURIPOTENT STEM CELL; MEGAKARYOPOIESIS; MESODERM; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR STRESS; STEM CELL SELF-RENEWAL; THROMBOCYTE ACTIVATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPOIESIS; UMBILICAL CORD BLOOD; ANIMAL; BIOREACTOR; BLOOD TRANSFUSION REACTION; CELL CULTURE TECHNIQUE; CELL LINE; CELL LINEAGE; DEVICES; IMMUNOLOGY; METABOLISM; PHENOTYPE; PROCEDURES; REGENERATIVE MEDICINE; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSPLANTATION;

ANIMALS; BIOREACTORS; BLOOD PLATELETS; CELL CULTURE TECHNIQUES; CELL LINE; CELL LINEAGE; CELL PROLIFERATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PHENOTYPE; PLATELET TRANSFUSION; REGENERATIVE MEDICINE; THROMBOPOIESIS; TRANSFUSION REACTION;

EID: 85026378542     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13736     Document Type: Article

References (95)

1. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006; 134: 453–66.
2. Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines: when to transfuse. Hematology Am Soc Hematol Educ Program 2013; 2013: 638–44.
3. Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, Mumford AD, Stanworth SJ, Tinegate H, British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2017; 176: 365–94.
4. Whitaker BI, Hinkins S. The 2011 National Blood Collection and Utilization Survey Report. Washington DC, USA: The United States Department of Health and Human Services, 2011.
5. Williamson LM, Devine DV. Challenges in the management of the blood supply. Lancet 2013; 381: 1866–75.
6. Japan Ministry of Health LaW. Simulation of Future Number of Blood Donors. http://www.mhlw.go.jp/stf/shingi2/0000070616.html, 2015. Accessed 13 April 2017.
7. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br J Haematol 2015; 171: 297–305.
8. Avanzi MP, Mitchell WB. Ex vivo production of platelets from stem cells. Br J Haematol 2014; 165: 237–47.
9. Lee EJ, Godara P, Haylock D. Biomanufacture of human platelets for transfusion: rationale and approaches. Exp Hematol 2014; 42: 332–46.
10. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science (New York, NY) 1998; 282: 1145–7.
11. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861–72.
12. Bluteau O, Langlois T, Rivera-Munoz P, Favale F, Rameau P, Meurice G, Dessen P, Solary E, Raslova H, Mercher T, Debili N, Vainchenker W. Developmental changes in human megakaryopoiesis. J Thromb Haemost 2013; 11: 1730–41.
13. Gaur M, Kamata T, Wang S, Moran B, Shattil SJ, Leavitt AD. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost 2006; 4: 436–42.
14. Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, Hiroyama T, Eto K, Nakauchi H. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008; 111: 5298–306.
15. Lu SJ, Li F, Yin H, Feng Q, Kimbrel EA, Hahm E, Thon JN, Wang W, Italiano JE, Cho J, Lanza R. Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res 2011; 21: 530–45.
16. Pick M, Azzola L, Osborne E, Stanley EG, Elefanty AG. Generation of megakaryocytic progenitors from human embryonic stem cells in a feeder- and serum-free medium. PLoS One 2013; 8: e55530.
17. Feng Q, Shabrani N, Thon JN, Huo H, Thiel A, Machlus KR, Kim K, Brooks J, Li F, Luo C, Kimbrel EA, Wang J, Kim KS, Italiano J, Cho J, Lu SJ, Lanza R. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem cell reports 2014; 3: 817–31.
18. Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, Fujita K, Koike T, Harimoto K, Dohda T, Watanabe A, Okita K, Takahashi N, Sawaguchi A, Yamanaka S, Nakauchi H, Nishimura S, Eto K. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell 2014; 14: 535–48.
19. Moreau T, Evans AL, Vasquez L, Tijssen MR, Yan Y, Trotter MW, Howard D, Colzani M, Arumugam M, Wu WH, Dalby A, Lampela R, Bouet G, Hobbs CM, Pask DC, Payne H, Ponomaryov T, Brill A, Soranzo N, Ouwehand WH, et al. Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. Nat Commun 2016; 7: 11208.
20. Zhou T, Benda C, Duzinger S, Huang Y, Li X, Li Y, Guo X, Cao G, Chen S, Hao L, Chan YC, Ng KM, Ho JC, Wieser M, Wu J, Redl H, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, et al. Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol 2011; 22: 1221–8.
21. Gourraud PA, Gilson L, Girard M, Peschanski M. The role of human leukocyte antigen matching in the development of multiethnic “haplobank” of induced pluripotent stem cell lines. Stem Cells 2012; 30: 180–6.
22. de Rham C, Villard J. Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. J Immunol Res 2014; 2014: 518135.
23. Center for iPS cell Reasearch and Application KU. iPS Cell Stock for Regenerative Medicine [Website]. https://www.cira.kyoto-u.ac.jp/e/research/stock.html. Accessed 13 April 2017.
24. Gras C, Schulze K, Goudeva L, Guzman CA, Blasczyk R, Figueiredo C. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum Gene Ther 2013; 24: 1018–28.
25. Zhang N, Zhi H, Curtis BR, Rao S, Jobaliya C, Poncz M, French DL, Newman PJ. CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes. Blood 2015; 127: 675–80.
26. Tozawa K, Ono-Uruga Y, Matsubara Y. Megakaryopoiesis. Clinical and Experimental Thrombosis and Hemostasis 2014; 1: 5.
27. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568–71.
28. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85: 402–13.
29. Cortin V, Pineault N, Garnier A. Ex vivo megakaryocyte expansion and platelet production from human cord blood stem cells. Methods Mol Biol 2009; 482: 109–26.
30. Mills JA, Paluru P, Weiss MJ, Gadue P, French DL. Hematopoietic differentiation of pluripotent stem cells in culture. Methods Mol Biol 2014; 1185: 181–94.
31. Notta F, Zandi S, Takayama N, Dobson S, Gan OI, Wilson G, Kaufmann KB, McLeod J, Laurenti E, Dunant CF, McPherson JD, Stein LD, Dror Y, Dick JE. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science (New York, NY). 2016; 351: aab2116.
32. Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL, Ema H, Nakauchi H. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell 2013; 154: 1112–26.
33. Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, Moore S, Carella C, Matsuoka S, Bouriez Jones T, Chowdhury O, Stenson L, Lutteropp M, Green JC, Facchini R, Boukarabila H, Grover A, Gambardella A, Thongjuea S, Carrelha J, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 2013; 502: 232–6.
34. Thompson A, Zhang Y, Kamen D, Jackson CW, Cardiff RD, Ravid K. Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization. J Biol Chem 1996; 271: 22976–82.
35. Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M, Sawaguchi A, Nagai R, Takahashi K, Yamanaka S, Nakauchi H, Eto K. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010; 207: 2817–30.
36. Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, Evan G. c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol 2002; 22: 6158–69.
37. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 3965–73.
38. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, Orkin SH. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695–704.
39. Matsubara Y, Murata M, Ikeda Y. Culture of megakaryocytes and platelets from subcutaneous adipose tissue and a preadipocyte cell line. Methods Mol Biol 2012; 788: 249–58.
40. Ono Y, Wang Y, Suzuki H, Okamoto S, Ikeda Y, Murata M, Poncz M, Matsubara Y. Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf. Blood 2012; 120: 3812–21.
41. Pulecio J, Alejo-Valle O, Capellera-Garcia S, Vitaloni M, Rio P, Mejia-Ramirez E, Caserta I, Bueren JA, Flygare J, Raya A. Direct conversion of fibroblasts to megakaryocyte progenitors. Cell Rep 2016; 17: 671–83.
42. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, Graf T, Italiano JE Jr, Shivdasani RA, von Andrian UH. Dynamic visualization of thrombopoiesis within bone marrow. Science (New York, NY). 2007; 317: 1767–70.
43. Kosaki G. Platelet production by megakaryocytes: protoplatelet theory justifies cytoplasmic fragmentation model. Int J Hematol 2008; 88: 255–67.
44. Thon JN, Montalvo A, Patel-Hett S, Devine MT, Richardson JL, Ehrlicher A, Larson MK, Hoffmeister K, Hartwig JH, Italiano JE Jr. Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol 2010; 191: 861–74.
45. Machlus KR, Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol 2013; 201: 785–96.
46. Nishimura S, Nagasaki M, Kunishima S, Sawaguchi A, Sakata A, Sakaguchi H, Ohmori T, Manabe I, Italiano JE Jr, Ryu T, Takayama N, Komuro I, Kadowaki T, Eto K, Nagai R. IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol 2015; 209: 453–66.
47. Di Buduo CA, Wray LS, Tozzi L, Malara A, Chen Y, Ghezzi CE, Smoot D, Sfara C, Antonelli A, Spedden E, Bruni G, Staii C, De Marco L, Magnani M, Kaplan DL, Balduini A. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. Blood 2015; 125: 2254–64.
48. Nakagawa Y, Nakamura S, Nakajima M, Endo H, Dohda T, Takayama N, Nakauchi H, Arai F, Fukuda T, Eto K. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes. Exp Hematol 2013; 41: 742–8.
49. Thon JN, Medvetz DA, Karlsson SM, Italiano JE Jr. Road blocks in making platelets for transfusion. J Thromb Haemost 2015; 13(Suppl. 1): S55–62.
50. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, Witte L, Hicklin DJ, Bohlen P, Eaton D, Lyden D, de Sauvage F, Rafii S. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64–71.
51. Zhang L, Urtz N, Gaertner F, Legate KR, Petzold T, Lorenz M, Mazharian A, Watson SP, Massberg S. Sphingosine kinase 2 (Sphk2) regulates platelet biogenesis by providing intracellular sphingosine 1-phosphate (S1P). Blood 2013; 122: 791–802.
52. Machlus KR, Johnson KE, Kulenthirarajan R, Forward JA, Tippy MD, Soussou TS, El-Husayni SH, Wu SK, Wang S, Watnick RS, Italiano JE Jr, Battinelli EM. CCL5 derived from platelets increases megakaryocyte proplatelet formation. Blood 2016; 127: 921–6.
53. Lasky LC, Sullenbarger B. Manipulation of oxygenation and flow-induced shear stress can increase the in vitro yield of platelets from cord blood. Tissue Eng Part C Methods 2011; 17: 1081–8.
54. Pineault N, Boucher JF, Cayer MP, Palmqvist L, Boyer L, Lemieux R, Proulx C. Characterization of the effects and potential mechanisms leading to increased megakaryocytic differentiation under mild hyperthermia. Stem Cells Dev 2008; 17: 483–93.
55. Thon JN, Dykstra BJ, Beaulieu LM. Platelet bioreactor: accelerated evolution of design and manufacture. Platelets 2017; 1–6.
56. Li Y, Ma T, Kniss DA, Yang ST, Lasky LC. Human cord cell hematopoiesis in three-dimensional nonwoven fibrous matrices: in vitro simulation of the marrow microenvironment. J Hematother Stem Cell Res 2001; 10: 355–68.
57. Weyrich AS, Zimmerman GA. Platelets in lung biology. Annu Rev Physiol 2013; 75: 569–91.
58. Lefrancais E, Ortiz-Munoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegue E, Looney MR. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 2017; 544: 105–9.
59. Dunois-Larde C, Capron C, Fichelson S, Bauer T, Cramer-Borde E, Baruch D. Exposure of human megakaryocytes to high shear rates accelerates platelet production. Blood 2009; 114: 1875–83.
60. Sullenbarger B, Bahng JH, Gruner R, Kotov N, Lasky LC. Prolonged continuous in vitro human platelet production using three-dimensional scaffolds. Exp Hematol 2009; 37: 101–10.
61. Thon JN, Mazutis L, Wu S, Sylman JL, Ehrlicher A, Machlus KR, Feng Q, Lu S, Lanza R, Neeves KB, Weitz DA, Italiano JE Jr. Platelet bioreactor-on-a-chip. Blood 2014; 124: 1857–1867.
62. Pallotta I, Lovett M, Kaplan DL, Balduini A. Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes. Tissue Eng Part C Methods 2011; 17: 1223–32.
63. Blin A, Le Goff A, Magniez A, Poirault-Chassac S, Teste B, Sicot G, Nguyen KA, Hamdi FS, Reyssat M, Baruch D. Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics. Sci Rep 2016; 6: 21700.
64. Avanzi MP, Oluwadara OE, Cushing MM, Mitchell ML, Fischer S, Mitchell WB. A novel bioreactor and culture method drives high yields of platelets from stem cells. Transfusion 2016; 56: 170–8.
65. Xi J, Zhu H, Liu D, Nan X, Zheng W, Liu K, Shi W, Chen L, Lv Y, Yan F, Li Y, Xie X, Wang Y, Yue W, Xu X, Wei X, Zhu J, Huang X, Pei X. Infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study. PLoS ONE 2013; 8: e54941.
66. Wang Y, Hayes V, Jarocha D, Sim X, Harper DC, Fuentes R, Sullivan SK, Gadue P, Chou ST, Torok-Storb BJ, Marks MS, French DL, Poncz M. Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale. Blood 2015; 125: 3627–36.
67. Baatout S, Chatelain B, Staquet P, Symann M, Chatelain C. Inhibition of actin polymerization by cytochalasin B induces polyploidization and increases the number of nucleolar organizer regions in human megakaryocyte cell lines. Anticancer Res 1998; 18: 459–64.
68. Avanzi MP, Goldberg F, Davila J, Langhi D, Chiattone C, Mitchell WB. Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulation. Br J Haematol 2014; 164: 867–76.
69. Macaulay IC, Thon JN, Tijssen MR, Steele BM, MacDonald BT, Meade G, Burns P, Rendon A, Salunkhe V, Murphy RP, Bennett C, Watkins NA, He X, Fitzgerald DJ, Italiano JE Jr, Maguire PB. Canonical Wnt signaling in megakaryocytes regulates proplatelet formation. Blood 2013; 121: 188–96.
70. Murphy AJ, Bijl N, Yvan-Charvet L, Welch CB, Bhagwat N, Reheman A, Wang Y, Shaw JA, Levine RL, Ni H, Tall AR, Wang N. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013; 19: 586–94.
71. Wang N, Tall AR. Cholesterol in platelet biogenesis and activation. Blood 2016; 127: 1949–53.
72. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, Denison MS, Schultz PG, Cooke MP. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science (New York, NY). 2010; 329: 1345–8.
73. Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DH, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood 2013; 122: 376–85.
74. Wagner JE Jr, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, Blazar BR, Tolar J, Le C, Jones J, Cooke MP, Bleul CC. Phase I/II Trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell 2016; 18: 144–55.
75. Strassel C, Brouard N, Mallo L, Receveur N, Mangin P, Eckly A, Bieche I, Tarte K, Gachet C, Lanza F. Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. Blood 2016; 127: 2231–40.
76. Matsunaga T, Tanaka I, Kobune M, Kawano Y, Tanaka M, Kuribayashi K, Iyama S, Sato T, Sato Y, Takimoto R, Takayama T, Kato J, Ninomiya T, Hamada H, Niitsu Y. Ex vivo large-scale generation of human platelets from cord blood CD34 + cells. Stem Cells 2006; 24: 2877–87.
77. Schlinker AC, Radwanski K, Wegener C, Min K, Miller WM. Separation of in-vitro-derived megakaryocytes and platelets using spinning-membrane filtration. Biotechnol Bioeng 2015; 112: 788–800.
78. Bergmeier W, Piffath CL, Cheng G, Dole VS, Zhang Y, von Andrian UH, Wagner DD. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 2004; 95: 677–83.
79. Nishikii H, Eto K, Tamura N, Hattori K, Heissig B, Kanaji T, Sawaguchi A, Goto S, Ware J, Nakauchi H. Metalloproteinase regulation improves in vitro generation of efficacious platelets from mouse embryonic stem cells. J Exp Med 2008; 205: 1917–27.
80. Hirata S, Murata T, Suzuki D, Nakamura S, Jono-Ohnishi R, Hirose H, Sawaguchi A, Nishimura S, Sugimoto N, Eto K. Selective Inhibition of ADAM17 efficiently mediates glycoprotein ibalpha retention during ex vivo generation of human induced pluripotent stem cell-derived platelets. Stem Cells Transl Med 2016; 5: 1–11.
81. Canault M, Duerschmied D, Brill A, Stefanini L, Schatzberg D, Cifuni SM, Bergmeier W, Wagner DD. p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood 2010; 115: 1835–42.
82. Brill A, Chauhan AK, Canault M, Walsh MT, Bergmeier W, Wagner DD. Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovasc Res 2009; 84: 137–44.
83. Oikawa S, Taguchi T, Endo K, Hoshi T, Kawashima W, Horibe Y, Urano S, Suzuki K, Minegishi M, Itoh T, Shimizu H. Storage of washed platelets in BRS-A platelet additive solutions based on two types of clinically available bicarbonated Ringer's solutions with different electrolyte concentrations. Transfus Apher Sci 2015; 53: 233–7.
84. Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, Saran F, Thurston J, Webb D. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 2011; 152: 35–51.
85. Pavenski K, Warkentin TE, Shen H, Liu Y, Heddle NM. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. Transfusion 2010; 50: 1552–60.
86. Ikeda N, Kojima H, Nishikawa M, Hayashi K, Futagami T, Tsujino T, Kusunoki Y, Fujii N, Suegami S, Miyazaki Y, Middleton D, Tanaka H, Saji H. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens 2015; 85: 252–9.
87. Borger AK, Eicke D, Wolf C, Gras C, Aufderbeck S, Schulze K, Engels L, Eiz-Vesper B, Schambach A, Guzman CA, Lachmann N, Moritz T, Martin U, Blasczyk R, Figueiredo C. Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions. Mol Med 2016; 22: 274–285.
88. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495–502.
89. Figueiredo C, Wedekind D, Muller T, Vahlsing S, Horn PA, Seltsam A, Blasczyk R. MHC universal cells survive in an allogeneic environment after incompatible transplantation. Biomed Res Int 2013; 2013: 796046.
90. Wiegmann B, Figueiredo C, Gras C, Pflaum M, Schmeckebier S, Korossis S, Haverich A, Blasczyk R. Prevention of rejection of allogeneic endothelial cells in a biohybrid lung by silencing HLA-class I expression. Biomaterials 2014; 35: 8123–33.
91. Weiss EH, Lilienfeld BG, Muller S, Muller E, Herbach N, Kessler B, Wanke R, Schwinzer R, Seebach JD, Wolf E, Brem G. HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation 2009; 87: 35–43.
92. Zhao L, Teklemariam T, Hantash BM. Heterelogous expression of mutated HLA-G decreases immunogenicity of human embryonic stem cells and their epidermal derivatives. Stem Cell Res 2014; 13: 342–54.
93. Metcalfe P. Platelet antigens and antibody detection. Vox Sang 2004; 87(Suppl. 1): 82–6.
94. Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol 2015; 171: 671–82.
95. Hayashi T, Hirayama F. Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping. Blood Transfus 2015; 13: 380–90.